Biomarin Pharmaceutical Inc annual revenue for fiscal TTM was $3.4 billion, an increase of 5.8% from $3.2 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Revenue (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $3.4B | $3.2B | $2.9B | $2.4B | $2.1B | $1.8B | $1.9B | $1.7B | $1.5B | $1.3B | $1.1B | $890M | $749M | $548M | $501M | $441M | $376M | $325M | $296M | $122M | $84M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Revenue (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $990M | $766M | $875M | $776M | $825M | $745M | $747M | $746M | $712M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More BMRN metrics: Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All BMRN financial statements → Interactive BMRN charts →
About TickerBase · Data methodology & sources · Privacy · Terms